HOXC6 and central nervous system cancer: The proliferation and migration ability of U87 and U251 cells with HOXC6 knockdown were significantly reduced, which would be beneficial for the use of HOXC6 as a therapeutic target to improve the prognosis, survival rate, and quality of life of glioma patients.